Report Overview

2023

Base Year

2017-2023

Historical Year

2024-2032

Forecast Year

Genetic Cardiomyopathies Market Outlook

The genetic cardiomyopathies market size was valued at USD 1.93 billion in 2023, driven by the rising emphasis on preventing cardiac failures. The market is expected to grow at a CAGR of 13.3% during the forecast period of 2024-2032, with the values likely to rise from USD 2.18 billion in 2024 to USD 5.93 billion by 2032.

Genetic Cardiomyopathies: Introduction

Genetic cardiomyopathy or familial hypertrophic cardiomyopathy is a heart condition that thickening of the cardiac muscle. In this case, the cardiac thickening usually occurs in the muscular wall (interventricular septum) that separates the left ventricle (lower chamber of heart) from right ventricle. Genetic cardiomyopathy may impede the flow of oxygen rich blood from the heart. This in turn, may lead to an abnormal heartbeat (arrhythmias) in the patients.

Common symptoms include chest pain, shortness of bread, palpitations, dizziness, or fainting. However, the symptoms differ from person to person, even within the same family. People suffering from genetic cardiomyopathy are at a sudden risk of death, despite having no symptoms.

Genetic Cardiomyopathies Market Analysis

Genetic cardiomyopathy is a commonly inherited cardiac illness, affecting approximately 2-5 in a 1000 people.  Non-pharmacological treatments like septal myectomy and alcohol septal ablation are frequently used to improve long-term quality of life in patients suffering from genetic cardiomyopathy. Over the years, significant advancements in the non-invasive and pharmacological treatment have been observed.

In 2023, the FDA approved a drug called Mavacamtem, popularly known as Camzyos, as a novel alternative for treating genetic cardiomyopathy. This new class drug, a myosin inhibitor, works by cutting down myosin levels which are present in abundance in the patients.

The genetic cardiomyopathies market value is expected to see a significant hike in the forecast period, with the rising emphasis on using novel techniques to fight the ailment. New study set-ups like induced pluripotent stem cells, three dimensional printing of cells, use of scaffolds and engineered heart tissue, are now being looked upon as a treatment alternative. Moreover, extensive knowledge on mutated proteins, protein quality control, and toxicity has opened new avenue of contemporary techniques like gene editing and repair using CRISPR Cas9, customised drugs and antisense therapies to develop an efficient and accurate treatment for the disease.

With a rising preference for precision medicine, researchers are now combining machine learning guided ECG and imaging analyses to facilitate new targeted drugs. Hence, we can a anticipate a substantial genetic cardiomyopathies market growth in the forecast period.

Genetic Cardiomyopathies Market Segmentation

Market Breakup by Disease Type

  • Dilated Cardiomyopathy
  • Hypertonic Cardiomyopathy
  • Restrictive Cardiomyopathy
  • Others

Market Breakup by Drug Type

  • Anticoagulants
  • Anti-Hypertensives
  • Antiarrhytensives
  • Cardiac Glycosides
  • Others

Market Breakup by Route of Administration

  • Oral
  • Topical

Market Breakup by End User

  • Hospitals
  • Clinics
  • Ambulatory Services Centres
  • Others

Market Breakup by Region-7MM

  • United States
  • EU-4 and the United Kingdom
  • Japan

Genetic Cardiomyopathies Market Overview

Genetic cardiomyopathy is a major cause of heart failure. With the rise in population, obesity, geriatric population, the North American region has been susceptible to number of heart failures, as a result, it has dominated the genetic cardiomyopathies market share in the historic period. Effective measures have been taken the government to mitigate the number of morbidities, which have been successful to an extent. Moreover, the presence of prominent healthcare market players has made a huge impact with regular research and conducting clinical trials to bring the best possible treatment for the patients.

In some cases, genetic cardiomyopathy may also lead to heart transplantation. Therefore, the Asian-pacific region can expect a hike in the forecast period, owing to its increasing popularity as medical tourism space. In addition, presence of an aging population is also fuelling investments and government initiatives to develop a quality infrastructure that can drive a prominent research and development in the contemporary treatment alternatives.

Genetic Cardiomyopathies Market: Competitor Landscape

The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:

  • Novartis International AG
  • Merck & Co.
  • Teva Pharmaceuticals
  • Mylan N.V
  • Bristo Myers Squibb Company
  • Boston Scientific Corporation
  • Sanofi S.A.
  • Becton, Dickinson and Company
  • Critical Care Diagnostics Inc.
  • Labcorp

Key Highlights of the Report

REPORT FEATURES DETAILS
Base Year 2023
Historical Period 2017-2023
Forecast Period 2024-2032
Scope of the Report

Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:

  • Disease Type
  • Drug Type
  • Route of Administration
  • End User
  • Region-7MM
Breakup by Disease Type
  • Dilated Cardiomyopathy
  • Hypertonic Cardiomyopathy
  • Restrictive Cardiomyopathy
  • Others
Breakup by Drug Type
  • Anticoagulants
  • Anti-Hypertensives
  • Antiarrhytensives
  • Cardiac Glycosides
  • Others
Breakup by Route of Administration
  • Oral
  • Topical
  • Others
Breakup by End User
  • Hospitals
  • Clinics
  • Ambulatory Services Centres
  • Others
Breakup by Region-7MM
  • United States
  • EU-4 and the United Kingdom
  • Japan
Market Dynamics
  • Market Drivers and Constraints
  • SWOT Analysis
  • Porter’s Five Forces Model 
  • Key Demand Indicators
  • Key Price Indicators
  • Industry Events, Initiatives, and Trends 
  • Value Chain Analysis
Competitive Landscape
  • Market Structure
  • Company Profiles
    • Financial Analysis
    • Product Portfolio
    • Demographic Reach and Achievements
    • Mergers and Acquisitions
    • Certifications
Companies Covered
  • Novartis International AG
  • Merck & Co.
  • Teva Pharmaceuticals
  • Mylan N.V
  • Bristo Myers Squibb Company
  • Boston Scientific Corporation
  • Becton
  • Dickinson and Company
  • Critical Care Diagnostics Inc.
  • Labcorp

Genetic Cardiomyopathies Market Report Snapshots

Genetic Cardiomyopathies Market Size

Genetic Cardiomyopathies Market Analysis

Genetic Cardiomyopathies Companies

*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*

Looking for specific insights?

Get in touch with us today for customized, data-driven solutions tailored to your unique requirements!

Key Questions Answered in the Report

The market attained a value of about USD 1.93 billion in 2023 driven by the rising focus on reducing the number of heart failures associated with genetic cardiomyopathies.

The market is anticipated to grow at a CAGR of 13.3% during the forecast period of 2024-2032, likely to reach a market value of USD 5.93 billion by 2032.

With the arrival of new medicines and techniques to treat genetic cardiomyopathies, the market has seen a substantial growth.

Recently, the FDA approved Mavacamtem, a new drug to treat genetic cardiomyopathy. Moreover, the integration of machine learning in diagnostics to develop precision medicine in the patients are the current market trends.

The major regions of the market include Japan, United States, EU-4 and the United Kingdom.

Major drug types used include anticoagulants, anti-hypertensives, antiarrhytensives, cardiac glycosides and others.

Dilated cardiomyopathy, hypertonic cardiomyopathy, restrictive cardiomyopathy, and others may affect patients.

Different routes of administration for the treatment market include oral and tropical.

The end users in the market include hospitals, clinics, and ambulatory services centres.

Key players involved in the market are Novartis International AG, Merck & Co., Teva Pharmaceuticals, Mylan N.V, Bristo Myers Squibb Company, Boston Scientific Corporation, Sanofi S.A., Becton, Dickinson and Company, Critical Care Diagnostics Inc., and Labcorp.

Purchase Full Report

Datasheet

 

USD 2,969

USD 2,699

tax inclusive*

  • Selected Sections, One User
  • Printing Not Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Single User License

One User

USD 5,499

USD 4,999

tax inclusive*

  • All Sections, One User
  • One Print Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Five User License

Five Users

USD 6,599

USD 5,999

tax inclusive*

  • All Sections, Five Users
  • Five Prints Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Corporate License

Unlimited Users

USD 7,699

USD 6,999

tax inclusive*

  • All Sections, Unlimited Users
  • Unlimited Prints Allowed
  • Email Delivery in PDF + Excel
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

How To Order

Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.

Select License Type

Choose the right license for your needs and access rights.

Click on ‘Buy Now’

Add the report to your cart with one click and proceed to register.

Select Mode of Payment

Choose a payment option for a secure checkout. You will be redirected accordingly.

Strategic Solutions for Informed Decision-Making

Connect For More Information

Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.

Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.

We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.

Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.

We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.

Back to top

We’re here to help answer any questions about our products and services.

Contact us

Locations


United States (Head Office)

30 North Gould Street, Sheridan, WY 82801

+1-415-325-5166

Australia

63 Fiona Drive, Tamworth, NSW

+61 448 06 17 27

India

C130 Sector 2 Noida, Uttar Pradesh 201301

+91-858-608-1494

Philippines

40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.

+63 287899028, +63 967 048 3306

United Kingdom

6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London

+44-753-713-2163

Vietnam

193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City

+84865399124